Q-omics provides the consensus-scored SNTG2 profile across patient tissues and cancer cell-line models. SNTG2 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, SNTG2 is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, SNTG2 RNA expression shows 11,768 significant gene co-expression associations, with the highest sampling consensus in STAD. Together, these results highlight HNSC, COAD, and STAD as cancer lineages where SNTG2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNTG2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNTG2 survival associations across molecular data types. SNTG2 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNTG2 RNA expression–survival associations across cancer types. High SNTG2 expression shows unfavorable associations in LGG, BLCA and KIRP, but favorable associations in HNSC, LUAD and ESCA. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for SNTG2 RNA expression.
This table summarizes SNTG2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for SNTG2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNTG2 shows lower tumor expression in COAD, THCA, LUAD, BLCA, BRCA and UCEC. The COAD box plot shows higher SNTG2 RNA expression in normal versus tumor tissue (log2 FC = −0.287, t-test p < 0.001).
This table shows molecular features associated with SNTG2 in patient tissues and cancer cell lines. In patient samples, SNTG2 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, SNTG2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Leukemia.
